Oxford Nanopore Misses First‑Half Revenue, Shares Slide Amid China Sales Decline
Oxford Nanopore misses first‑half revenue target as Chinese sales slump, yet keeps full‑year guidance steady, underscoring its resilience in molecular detection tech.
- OXFORD NANOPORE TECHNOLOGIES
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read